🎉 M&A multiples are live!
Check it out!

Eupraxia Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Eupraxia Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Eupraxia Pharmaceuticals Overview

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.


Founded

2011

HQ

Canada
Employees

33

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$107M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Eupraxia Pharmaceuticals Financials

Eupraxia Pharmaceuticals has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Eupraxia Pharmaceuticals achieved revenue of n/a and an EBITDA of -$17.5M.

Eupraxia Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Eupraxia Pharmaceuticals valuation multiples based on analyst estimates

Eupraxia Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$19.3M -$17.5M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$12.0M -$19.7M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Eupraxia Pharmaceuticals Stock Performance

As of April 15, 2025, Eupraxia Pharmaceuticals's stock price is CAD 4 (or $3).

Eupraxia Pharmaceuticals has current market cap of CAD 154M (or $108M), and EV of CAD 152M (or $107M).

See Eupraxia Pharmaceuticals trading valuation data

Eupraxia Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$107M $108M XXX XXX XXX XXX $-0.70

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Eupraxia Pharmaceuticals Valuation Multiples

As of April 15, 2025, Eupraxia Pharmaceuticals has market cap of $108M and EV of $107M.

Eupraxia Pharmaceuticals's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Eupraxia Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Eupraxia Pharmaceuticals and 10K+ public comps

Eupraxia Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $107M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -6.1x XXX XXX XXX
P/E -6.0x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -5.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Eupraxia Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Eupraxia Pharmaceuticals Valuation Multiples

Eupraxia Pharmaceuticals's NTM/LTM revenue growth is Infinity%

Eupraxia Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.6M for the same period.

Over next 12 months, Eupraxia Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Eupraxia Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Eupraxia Pharmaceuticals and other 10K+ public comps

Eupraxia Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -10% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.6M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Eupraxia Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Drug Delivery Systems comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Eupraxia Pharmaceuticals M&A and Investment Activity

Eupraxia Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Eupraxia Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Eupraxia Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Eupraxia Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Eupraxia Pharmaceuticals

When was Eupraxia Pharmaceuticals founded? Eupraxia Pharmaceuticals was founded in 2011.
Where is Eupraxia Pharmaceuticals headquartered? Eupraxia Pharmaceuticals is headquartered in Canada.
How many employees does Eupraxia Pharmaceuticals have? As of today, Eupraxia Pharmaceuticals has 33 employees.
Who is the CEO of Eupraxia Pharmaceuticals? Eupraxia Pharmaceuticals's CEO is Dr. James A. Helliwell, M.D..
Is Eupraxia Pharmaceuticals publicy listed? Yes, Eupraxia Pharmaceuticals is a public company listed on TSE.
What is the stock symbol of Eupraxia Pharmaceuticals? Eupraxia Pharmaceuticals trades under EPRX ticker.
When did Eupraxia Pharmaceuticals go public? Eupraxia Pharmaceuticals went public in 2021.
Who are competitors of Eupraxia Pharmaceuticals? Similar companies to Eupraxia Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Eupraxia Pharmaceuticals? Eupraxia Pharmaceuticals's current market cap is $108M
Is Eupraxia Pharmaceuticals profitable? Yes, Eupraxia Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.